Rare Disease Innovation at the FDA-Opportunities for Implementation.

Q1 Medicine Journal of the American Medical Association Pub Date : 2024-12-17 DOI:10.1001/jama.2024.20358

Carolyn K Shore, Tequam L Worku, Jeffrey Kahn

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

FDA 的罕见病创新--实施机会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of the American Medical Association Medicine-Medicine (all)

CiteScore

45.40

自引率

0.00%

发文量

期刊介绍： JAMA, published continuously since 1883, is an international peer-reviewed general medical journal. JAMA is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.

期刊最新文献

Cardiovascular Disease Deaths Climb in Rural US, Particularly Among Younger Adults. FDA Seeks to Remove Oral Phenylephrine From Decongestants. GLP-1 Agonists May Reduce Risk of Alcohol Use Disorder Hospitalizations. Internet Use May Boost Mental Health Benefits in Older Adults. US Life Expectancy Gap Among Demographics Was Up to 20 Years in 2021.